Long-Term Clinical and Endoscopic Outcomes in True North Week 52 Clinical Remitters Over 3 Years of Treatment With Ozanimod: An Interim Analysis of the True North Open-Label Extension Study

被引：0
|
作者：
Afzali, Anita [1 ]
Rubin, David T. [2 ]
Abreu, Maria T. [3 ]
Chiorean, Michael V. [4 ]
Akukwe, Lucy [5 ]
Jain, Anjali [5 ]
Petersen, AnnKatrin [5 ]
Osterman, Mark T. [5 ]
Wu, Hsiuanlin [5 ]
Danese, Silvio [6 ]
Panaccione, Remo [7 ]
机构：
[1] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[2] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[3] Univ Miami, Miller Sch Med, Miami, FL USA
[4] Swedish Med Ctr, Inflammatory Bowel Dis Ctr, Seattle, WA USA
[5] Bristol Myers Squibb, Princeton, NJ USA
[6] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Milan, Italy
[7] Univ Calgary, Calgary, AB, Canada
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S852
引用
收藏
页码：S630 / S631
页数：2
相关论文
共 50 条
  • [1] Durability of Symptomatic and Clinical Outcomes in Ozanimod- Treated Patients by Endpoints of Increasing Objectivity at True North Week 52: Interim Analysis of the True North Open-Label Extension Study
    Abreu, Maria T.
    Panaccione, Remo
    Vermeire, Severine
    Rubin, David T.
    Mehra, Dimpy
    Wu, Hsiuanlin
    Osterman, Mark T.
    Ahmad, Harris A.
    Jain, Anjali
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S698 - S699
  • [2] Extended induction in the True North open-label extension study: clinical outcomes of ∼2 years of ozanimod treatment
    Vermeire, S.
    Colombel, J. F.
    Chiorean, M. V.
    Ghosh, S.
    Jain, A.
    Lawlor, G.
    Osterman, M. T.
    Wu, H.
    Canavan, J. B.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 903 - 904
  • [3] EXTENDED INDUCTION IN THE TRUE NORTH OPEN-LABEL EXTENSION STUDY: CLINICAL OUTCOMES OF ∼2 YEARS OF OZANIMOD TREATMENT
    Rubin, David T.
    Colombel, Jean Frederic
    Chiorean, Michael V.
    Ghosh, Subrata
    Jain, Anjali
    Lawlor, Garrett
    Osterman, Mark T.
    Wu, Hsiuanlin
    Canavan, James B.
    Vermeire, Severine
    GASTROENTEROLOGY, 2023, 164 (06) : S1102 - S1102
  • [4] Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
    Danese, S.
    Abreu, M. T.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Panaccione, R.
    Afzali, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I101 - I102
  • [5] Efficacy and safety of 3 years of continuous ozanimod treatment: An interim analysis of the True North open-label extension study
    Danese, S.
    Sparrow, M.
    Abreu, M. T.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Panaccione, R.
    Afzali, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 121 - 122
  • [6] LONG-TERM SAFETY OF 3 YEARS OF OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Abreu, Maria T.
    Danese, Silvio
    Wolf, Douglas C.
    Canavan, James B.
    Jain, Anjali
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Afzali, Anita
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S208 - S208
  • [7] Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
    Panaccione, R.
    Danese, S.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Afzali, A.
    Abreu, M. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 534 - 534
  • [8] Efficacy and Safety of 2 Years of Continuous Ozanimod Treatment: Interim Analysis of the True North Open-Label Extension Study
    Abreu, Maria T.
    Dulai, Parambir
    Dignass, Axel
    Savarino, Edoardo
    Hudesman, David
    Afzali, Anita
    Jairath, Vipul
    Osterman, Mark
    Akukwe, Lucy
    Liu, W. Jerry
    Memaj, Arteid
    Petersen, AnnKatrin
    Jain, Anjali
    Canavan, James B.
    Vermeire, Severine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S537 - S537
  • [9] Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
    D'Haens, G.
    Sands, B. E.
    Ferrante, M.
    Matsuoka, K.
    Lindsay, J. O.
    Blumenstein, I.
    Mehra, D.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    Hanauer, S. B.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1814 - I1815
  • [10] Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension
    Siegel, C.
    Danese, S.
    Rubin, D. T.
    Sabino, J.
    Long, M. D.
    Cross, R. K.
    Armuzzi, A.
    Blumenstein, I.
    Kobayashi, T.
    Lama, S.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I100 - I101
12345